TNFRSF9 and neoplasm: Brown and colleagues designed a 4-1BB (CD137) co-stimulatory CAR (IL13BBѯ) and a manufacturing platform using enriched central memory T cells to confirm that IL13Ra2-targeted CAR-T enhanced anti-tumor effect sin patient-derived tumor models (Brown et al., 2016; Brown et al., 2018).